Integrin αvβ3-targeted radioimmunotherapy of glioblastoma multiforme

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7330-7339

  Veeravagu, Anand ^a,b   Liu, Zhaofei ^c   Niu, Gang ^a   Chen, Kai ^a   Jia, Bing ^c   Cai, Weibo ^a   Jin, Cunjing ^c   Hsu, Andrew R ^a   Connolly, Andrew J ^b   Tse, Victor ^b   Wang, Fan ^c   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABEGRIN YTTRIUM 90; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; YTTRIUM 90; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA FRAGMENTATION; DNA SYNTHESIS; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NICK END LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; ANIMAL; BRAIN TUMOR; DRUG EFFECT; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METHODOLOGY; NUDE MOUSE; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149329018     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0797     Document Type: Article

References (56)

1. Stark AM, Nabavi A, Mehdorn HM, Blomer U. Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 2005;63:162-9.
2. Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 2006;20:E5.
3. Santarelli JG, Sarkissian V, Hou LC, Veeravagu A, Tse V. Molecular events of brain metastasis. Neurosurg Focus 2007;22:E1.
4. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
5. 3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 2005;11:6270-9.
6. 3 antagonists for anti-angiogenic cancer treatment. Recent Patents Anticancer Drug Discov 2007;2:143-58.
7. Lim M, Guccione S, Haddix T, et al. ávâ3 Integrin in central nervous system tumors. Hum Pathol 2005;36:665-9.
8. Mahabeleshwar GH, Feng W, Reddy K, Plow EF, Byzova TV. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ Res 2007;101:570-80.
9. Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am J Pathol 2005;167:1379-87.
10. Brem RB, Robbins SG, Wilson DJ, et al. Immunolocalization of integrins in the human retina. Invest Ophthalmol Vis Sci 1994;35:3466-74.
11. Oka N, Soeda A, Inagaki A, et al. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 2007;360:553-9.
12. 3. Cancer Res 2006;66:9673-81.
13. 3 integrin agents. J Neurooncol 2000;46:135-44.
14. 3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A 2003;100:14205-10.
15. 3 correlates with actin cytoskeleton in primary cultures of human breast cancer. Cancer Cell Int 2007;7:16.
16. 3 Integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996;63:169-73.
17. 1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol 2007;212:368-74.
18. 3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma. World J Gastroenterol 2008;14:421-7.
19. 3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 2007;28:443-9.
20. Sathornsumetee S, Cao Y, Marcello JE, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008;26:271-8.
21. 3-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis 2008;25:53-64.
22. Harris TD, Kalogeropoulos S, Nguyen T, et al. Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy. Cancer Biother Radiopharm 2003;18:627-41.
23. Fu Y, Ponce ML, Thill M, Yuan P, Wang NS, Csaky KG. Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD 478761. Invest Ophthalmol Vis Sci 2007;48:5184-90.
24. Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 2006;59:1304-12.
25. 3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 2002;62:4263-72.
26. 3. Clin Cancer Res 2000;6:3056-61.
27. 3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 2006;5:3122-9.
28. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin inmalignant glioma patients: a pilot study. Br J Cancer 2002;86:207-12.
29. Julow J, Backlund EO, Lanyi F, et al. Long-term results and late complications after intracavitary yttrium-90 colloid irradiation of recurrent cystic craniopharyngiomas. Neurosurgery 2007;61:288-95.
30. Zinzani PL, Tani M, Fanti S, et al. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. Cancer 2008;112:856-62.
31. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007;110:2528-34.
32. Pitini V, Baldari S, Altavilla G, Arrigo C, Naro C, Perniciaro F. Salvage therapy for primary central nervous system lymphoma with 90Y-Ibritumomab and Temozolomide. J Neurooncol 2007;3:291-3.
33. Kuzel TM, Rosen ST. Radioimmunotherapy of lymphoma. Cancer Treat Res 1993;68:1-12.
34. Wagner HN, Jr., Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002;43:267-72.
35. Martensson L, Wang Z, Nilsson R, et al. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clin Cancer Res 2005;11:7104-8s.
36. Chen X, Park R, Khankaldyyan V, et al. Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. Mol Imaging Biol 2006;8:9-15.
37. 3-targeted imaging of lung cancer. Neoplasia 2005;7:271-9.
38. 3 expression. Bioconjug Chem 2007;18:1987-94.
39. Krishnan A, Nademanee A, Fung HC, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90-5.
40. Neff R, Abdel-Misih R, Khatri J, et al. The toxicity of liver directed yttrium-90 microspheres in primary and metastatic liver tumors. Cancer Invest 2008;26:173-7.
41. Zinzani PL, Tani M, Fanti S, et al. A phase II trial of CHOP chemotherapy followed by yttrium-90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. Ann Oncol. Epub ahead of print 2008 Feb 25.
42. Goldenberg DM, Griffiths GL. Radioimmunotherapy of cancer: arming the missiles. J Nucl Med 1992;33:1110-2.
43. 3 receptor antagonist: different but biologically equivalent. Bioconjug Chem 2004;15:235-41.
44. 90Y-ibritumomab tiuxetan (Zevalin). J Exp Ther Oncol 2004;4:305-16.
45. 18F-FDG. J Nucl Med 2005;46:945-52.
46. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
47. Saga T, Kawashima H, Araki N, et al. Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 2006;31:774-80.
48. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J Nucl Med 2005;36:1902-9.
49. Brechbiel MW. Targeted α-therapy: past, present, future? Dalton Trans 2007;4918-28.
50. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 1998;16:3691-710.
51. 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med Mol Imaging 2004;48:220-8.
52. 90Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 2005;2:125-31.
53. Paganelli G, Grana C, Chinol M, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med 1999;26: 348-57.
54. Williams JA, Edwards JA, Wessels BW, et al. Targeting and therapy of human glioma xenografts in vivo using radiolabeled antibodies. Int J Radiat Oncol Biol Phys 1990;19:633-42.
55. 3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery 2003;52:177-85.
56. v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002;98:690-7.